Kymera Therapeutics (NASDAQ:KYMR) Receives "Buy" Rating from Guggenheim

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at Guggenheim in a research note issued to investors on Monday,Benzinga reports. They currently have a $52.00 price target on the stock. Guggenheim's price objective would suggest a potential upside of 74.79% from the stock's current price.

Other research analysts have also recently issued research reports about the stock. Stephens restated an "overweight" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Citigroup assumed coverage on Kymera Therapeutics in a research report on Thursday, March 13th. They issued a "buy" rating and a $52.00 price target on the stock. Finally, HC Wainwright lifted their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a report on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $55.27.

Kymera Therapeutics Stock Down 4.5%

Kymera Therapeutics stock traded down $1.39 during mid-day trading on Monday, reaching $29.75. The company had a trading volume of 383,256 shares, compared to its average volume of 562,720. The company has a 50 day moving average of $29.48 and a 200-day moving average of $37.31. Kymera Therapeutics has a 52 week low of $19.45 and a 52 week high of $53.27. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of -12.71 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.10. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. During the same period in the previous year, the company posted ($0.69) earnings per share. The company's quarterly revenue was up 114.6% compared to the same quarter last year. On average, analysts predict that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 1,383 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the transaction, the chief operating officer now owns 67,800 shares in the company, valued at approximately $2,064,510. This trade represents a 2.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the transaction, the chief financial officer now owns 201,886 shares of the company's stock, valued at approximately $6,147,428.70. This represents a 3.37% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,659 shares of company stock valued at $324,567. 15.82% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Blue Trust Inc. raised its position in shares of Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after purchasing an additional 270 shares during the period. State of Wyoming acquired a new stake in Kymera Therapeutics during the 4th quarter worth approximately $45,000. GF Fund Management CO. LTD. bought a new position in Kymera Therapeutics in the fourth quarter valued at approximately $55,000. KBC Group NV lifted its stake in Kymera Therapeutics by 15.2% in the first quarter. KBC Group NV now owns 2,479 shares of the company's stock valued at $68,000 after buying an additional 328 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Kymera Therapeutics in the first quarter valued at approximately $68,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.